Electronic Authorization: Finance Reliability and the Right to Challenge

CMS’s early-adopter network brings several participants in the authorization pathway into an implementation effort. The initiative is evidence of coordination activity, not proof that every connected workflow now performs reliably.

I would require an operating agreement covering incomplete submissions, unavailable counterparties and conflicting status information. Each failure needs an owner and a usable next step. Without that agreement, technical integration can leave the same unresolved work in a different queue.

The buyer should evaluate both elapsed time and accumulated effort across payer and provider teams. A local productivity gain is less valuable when it generates additional calls, corrections or delays outside the measured department.

Automation in claims and authorization raises questions about how a person or organization can challenge a consequential decision. The KFF analysis cited here describes a policy landscape that must be assessed for the relevant jurisdiction; it should not be treated as a single uniform legal standard.

I would separate the system’s administrative assistance from the authority to determine coverage. Source evidence, applicable criteria, material changes and reviewer actions should remain retrievable. This is necessary for operational review even where the technology itself is not making the final determination.

The cost model should include challenges and corrections. If the projected margin depends on discouraging appeals or transferring review work to an unfunded provider team, the proposal is misaligned with the service it claims to improve.

Bayesian Health’s FDA clearance for a continuous sepsis monitor is a regulated-product milestone. It does not establish effectiveness or financial value for adjacent administrative products, and it does not remove the need for evaluation in a particular care environment.

The transferable discipline is to define intended use, evidence requirements and post-deployment responsibilities. A buyer should identify how performance will be assessed when patient mix, documentation or workflow changes, and who can pause use when assumptions fail.

I would carry that discipline into administrative procurement without implying that clinical and administrative risks are identical. The relevant controls should follow the decision’s consequences and the institution’s retained responsibilities.

FHIR support establishes a technical capability. The economic case still depends on request completeness, decision usability and the proportion of cases that need manual recovery. A narrow automated subset can produce attractive metrics while leaving total staffing unchanged.

I would retain unsupported, failed and abandoned requests in the operating denominator and report results by case complexity. This makes it possible to distinguish genuine productivity from selection of easier work.

Expansion should depend on lower total administrative effort and reliable access within the supported scope. Where the system remains dependent on extensive manual recovery, the next investment should address the specific failure before increasing transaction volume.